Biotechnology & Gene Editing

Having examined autonomous vehicles and the convergence of AI, sensing, and control systems in transportation, this chapter turns to biotechnology, a domain defined by fundamentally different innovation dynamics rooted in molecular biology and regulatory constraints.

Biotechnology occupies a distinctive position within the patent system. Unlike most technology domains where the path from invention to commercialization is relatively direct, biotech patents frequently emerge from basic scientific research conducted at universities and government laboratories, traverse lengthy regulatory approval processes, and raise profound ethical questions about the boundaries of patentable subject matter. This chapter examines the trajectory of biotechnology and gene editing patents — from the recombinant DNA revolution of the 1970s through the genomic era and the current frontier of precision gene editing.

The leading biotechnology patent holders pursue distinct strategic approaches. Some organizations concentrate heavily on gene editing and modification technologies, while others maintain diversified portfolios spanning recombinant DNA, enzyme engineering, and nucleic acid detection. A comparison of subfield portfolios across major holders reveals the strategic choices that define each organization's approach to biotech innovation and identifies subfields where competitive intensity is highest.

A defining characteristic of platform technologies is their diffusion into multiple sectors of the economy. By tracking how frequently biotechnology-classified patents also carry CPC codes from non-biotech technology areas, it is possible to measure the spread of biotech methods into healthcare delivery, agriculture, industrial chemistry, and other domains. The breadth of this diffusion provides evidence for biotechnology's role as a foundational technology with applications far beyond its immediate field.

Biotechnology patents increasingly involve larger inventor teams, reflecting the multidisciplinary nature of modern life sciences research. Comparing team sizes between biotech and non-biotech patents reveals how the collaborative demands of genetic engineering, clinical trials, and regulatory compliance shape the structure of inventive activity in the life sciences.

Biotechnology and gene editing patents occupy a distinctive position at the intersection of innovation policy, bioethics, and public health regulation. The Supreme Court's decision in Association for Molecular Pathology v. Myriad Genetics (2013) established that naturally occurring DNA sequences cannot be patented, while synthetic cDNA remains patentable — a distinction that continues to shape patent strategy in genomics. The ongoing CRISPR patent dispute between the Broad Institute and the University of California illustrates how foundational biotech patents can become the subject of protracted legal battles with substantial commercial value at stake.

Gene editing technologies raise particularly acute ethical questions. The ability to modify human germline cells — changes that would be inherited by future generations — has prompted international calls for moratoriums and regulatory frameworks that have no parallel in other technology domains. These ethical and regulatory dimensions create distinctive constraints on how biotech patents translate into products and therapies, distinguishing the field from domains such as artificial intelligence or semiconductors where the path from patent to market is less encumbered by ethical oversight.